Alan P. Alfano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alan P. Alfano has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Ann Gill Taylor
Center for the Study of Complementary and Alternative Therapies University of Virginia, Charlottesville, VA
1 shared publicationGeneviève G. McConnell
Department of Physical Medicine and Rehabilitation, University of Virginia Health System, Charlottesville, VA
1 shared publicationGeorge T. Gillies
Department of Mechanical and Aerospace Engineering, University of Virginia, Charlottesville, Va
1 shared publicationMark R. Conaway
Department of Health Evaluation Sciences, University of Virginia, Charlottesville, VA
1 shared publicationPamela A. Foresman
Center for the Study of Complementary and Alternative Therapies University of Virginia, Charlottesville, VA
1 shared publicationPhilomena R. Dunkl
Center for the Study of Complementary and Alternative Therapies University of Virginia, Charlottesville, VA
1 shared publication
Latest Publications
- 1 February 2001
- Published by SAGE Publications in The Journal of Alternative and Complementary Medicine
- Vol. 7 (1) , 53-64
Static Magnetic Fields for Treatment of Fibromyalgia: A Randomized Controlled Trial
Objective: To test effectiveness of static magnetic fields of two different configurations, produced by magnetic sleep pads, as adjunctive therapies in decreasing patient pain perception and improving functional status in individuals with fibromyalgia. Design: Randomized, placebo-controlled, 6-month trial conducted from November 1997 through December 1998. Setting and subjects: Adults who met the 1990 American College of Rheumatology criteria for fibromyalgia were recruited through clinical referral and media announcements and evaluated at a university-based clinic. Interventions: Subjects in Functional Pad A group used a pad for 6 months that provided whole-body exposure to a low, uniform static magnetic field of negative polarity. Subjects in the Functional Pad B group used a pad for 6 months that exposed them to a low static magnetic field that varied spatially and in polarity. Subjects in two Sham groups used pads that were identical in appearance and texture to the functional pads but contained inactive magnets; these groups were combined for analysis. Subjects in the Usual Care group continued with their established treatment regimens. Outcome measures: Primary outcomes were the change scores at 6 months in the following measures: functional status (Fibromyalgia Impact Questionnaire), pain intensity ratings, tender point count, and a tender point pain intensity score. Results: There was a significant difference among groups in pain intensity ratings (p = 0.03), with Functional Pad A group showing the greatest reduction from baseline at 6 months. All four groups showed a decline in number of tender points, but differences among the groups were not significant (p = 0.72). The functional pad groups showed the largest decline in total tender point pain intensity, but overall differences were not significant (p = 0.25). Improvement in functional status was greatest in the functional pad groups, but differences among groups were not significant (p = 0.23). Conclusions: Although the functional pad groups showed improvements in functional status, pain intensity level, tender point count, and tender point intensity after 6 months of treatment, with the exception of pain intensity level these improvements did not differ significantly from changes in the Sham group or in the Usual Care group.
- 1 February 2001
- Published by SAGE Publications in The Journal of Alternative and Complementary Medicine
- Vol. 7 (1) , 53-64
Static Magnetic Fields for Treatment of Fibromyalgia: A Randomized Controlled Trial
Objective: To test effectiveness of static magnetic fields of two different configurations, produced by magnetic sleep pads, as adjunctive therapies in decreasing patient pain perception and improving functional status in individuals with fibromyalgia. Design: Randomized, placebo-controlled, 6-month trial conducted from November 1997 through December 1998. Setting and subjects: Adults who met the 1990 American College of Rheumatology criteria for fibromyalgia were recruited through clinical referral and media announcements and evaluated at a university-based clinic. Interventions: Subjects in Functional Pad A group used a pad for 6 months that provided whole-body exposure to a low, uniform static magnetic field of negative polarity. Subjects in the Functional Pad B group used a pad for 6 months that exposed them to a low static magnetic field that varied spatially and in polarity. Subjects in two Sham groups used pads that were identical in appearance and texture to the functional pads but contained inactive magnets; these groups were combined for analysis. Subjects in the Usual Care group continued with their established treatment regimens. Outcome measures: Primary outcomes were the change scores at 6 months in the following measures: functional status (Fibromyalgia Impact Questionnaire), pain intensity ratings, tender point count, and a tender point pain intensity score. Results: There was a significant difference among groups in pain intensity ratings (p = 0.03), with Functional Pad A group showing the greatest reduction from baseline at 6 months. All four groups showed a decline in number of tender points, but differences among the groups were not significant (p = 0.72). The functional pad groups showed the largest decline in total tender point pain intensity, but overall differences were not significant (p = 0.25). Improvement in functional status was greatest in the functional pad groups, but differences among groups were not significant (p = 0.23). Conclusions: Although the functional pad groups showed improvements in functional status, pain intensity level, tender point count, and tender point intensity after 6 months of treatment, with the exception of pain intensity level these improvements did not differ significantly from changes in the Sham group or in the Usual Care group.